Has the Danish Healthcare Sector valuation changed over the past few years?

Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 12.6x which is lower than its 3-year average PE of 29.0x. The 3-year average PS ratio of 8.4x is higher than the industry's current PS ratio of 4.0x.

Which industries have driven the changes within the Danish Healthcare sector?

Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.9x. Analysts are expecting annual earnings growth of 20.1%, which is higher than its past year's earnings growth of 0.3% per year.

Danish (OMX) Healthcare Sector Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 12 Jul 2026	DKK 1.9t	DKK 469.2b	DKK 147.1b	20.6x	12.6x	4x
Tue, 09 Jun 2026	DKK 1.6t	DKK 468.9b	DKK 147.1b	19.7x	11x	3.5x
Thu, 07 May 2026	DKK 1.7t	DKK 466.4b	DKK 149.5b	20.7x	11.5x	3.7x
Sat, 04 Apr 2026	DKK 1.5t	DKK 447.8b	DKK 130.0b	17.4x	11.3x	3.3x
Mon, 02 Mar 2026	DKK 1.5t	DKK 447.7b	DKK 130.9b	18.7x	11.5x	3.3x
Wed, 28 Jan 2026	DKK 2.2t	DKK 453.1b	DKK 136.7b	17.9x	16.5x	5x
Fri, 26 Dec 2025	DKK 2.0t	DKK 453.7b	DKK 136.8b	17.1x	14.4x	4.3x
Sun, 23 Nov 2025	DKK 1.9t	DKK 454.3b	DKK 137.1b	17.1x	13.5x	4.1x
Tue, 21 Oct 2025	DKK 2.1t	DKK 447.6b	DKK 141.7b	19.1x	14.9x	4.7x
Thu, 18 Sep 2025	DKK 2.1t	DKK 447.1b	DKK 141.6b	18.9x	15x	4.8x
Sat, 16 Aug 2025	DKK 1.9t	DKK 444.4b	DKK 140.3b	28.1x	13.6x	4.3x
Mon, 14 Jul 2025	DKK 2.4t	DKK 423.1b	DKK 124.5b	29.9x	19.3x	5.7x
Wed, 11 Jun 2025	DKK 2.8t	DKK 423.7b	DKK 124.7b	31.2x	22.4x	6.6x
Fri, 09 May 2025	DKK 2.3t	DKK 422.8b	DKK 124.7b	21.4x	18.8x	5.5x
Sun, 06 Apr 2025	DKK 2.4t	DKK 409.5b	DKK 121.3b	22.8x	19.4x	5.8x
Tue, 04 Mar 2025	DKK 3.4t	DKK 410.0b	DKK 121.4b	28x	27.8x	8.2x
Thu, 30 Jan 2025	DKK 3.3t	DKK 387.4b	DKK 111.3b	28.9x	29.2x	8.4x
Sat, 28 Dec 2024	DKK 3.4t	DKK 387.4b	DKK 111.3b	29.9x	30.1x	8.7x
Mon, 25 Nov 2024	DKK 3.9t	DKK 387.4b	DKK 111.3b	31x	34.9x	10x
Wed, 23 Oct 2024	DKK 4.1t	DKK 372.2b	DKK 107.2b	35.4x	38.6x	11.1x
Fri, 20 Sep 2024	DKK 4.6t	DKK 371.9b	DKK 107.1b	36.7x	42.9x	12.4x
Sun, 18 Aug 2024	DKK 4.7t	DKK 370.7b	DKK 107.0b	37.2x	43.9x	12.7x
Tue, 16 Jul 2024	DKK 4.9t	DKK 355.2b	DKK 106.2b	35.5x	46.2x	13.8x
Thu, 13 Jun 2024	DKK 4.9t	DKK 355.3b	DKK 106.2b	36.4x	46.3x	13.9x
Sat, 11 May 2024	DKK 4.5t	DKK 354.9b	DKK 106.0b	34.6x	42.5x	12.7x
Mon, 08 Apr 2024	DKK 4.5t	DKK 341.2b	DKK 99.6b	37.4x	44.7x	13x
Wed, 06 Mar 2024	DKK 4.4t	DKK 340.0b	DKK 98.9b	38.2x	44.6x	13x
Fri, 02 Feb 2024	DKK 4.0t	DKK 320.8b	DKK 90.1b	32x	44.7x	12.6x
Sun, 31 Dec 2023	DKK 3.6t	DKK 320.4b	DKK 90.0b	32.8x	40.4x	11.3x
Tue, 28 Nov 2023	DKK 3.7t	DKK 320.5b	DKK 90.0b	33.2x	40.9x	11.5x
Thu, 26 Oct 2023	DKK 3.6t	DKK 305.6b	DKK 82.3b	26.6x	43.4x	11.7x
Sat, 23 Sep 2023	DKK 3.4t	DKK 305.5b	DKK 82.2b	33.8x	41.3x	11.1x
Mon, 21 Aug 2023	DKK 3.3t	DKK 303.2b	DKK 81.2b	36.8x	40.8x	10.9x
Wed, 19 Jul 2023	DKK 2.9t	DKK 286.9b	DKK 75.4b	39x	38.7x	10.2x


DK Market	-1.44%
Healthcare	-1.24%
Life Sciences	3.96%
Medical Equipment	-0.23%
Biotech	-1.31%
Pharma	-1.39%
Healthtech	-3.30%
Healthcare Services	-6.69%

Company	Last Price	7D	1Y	Valuation
COLO B Coloplast	DKK 401.00	1.5% +DKK 1.4b	-33.2%	PE42.9x
AMBU B Ambu	DKK 68.60	2.9% +DKK 514.5m	-28.7%	PE37.9x
GUBRA Gubra	DKK 355.60	8.4% +DKK 450.8m	-14.3%	PE3.4x
CHEMM ChemoMetec	DKK 409.80	0.6% +DKK 41.8m	-23.8%	PE40.3x

Announcement • 12h

Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig (Mim8) In Phase 3 Hemophilia a Frontier Extension Study

Novo Nordisk unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8) subcutaneous prophylaxis in children, adolescents, and adults with hemophilia A, with or without inhibitors, across a range of dosing frequencies including once-monthly, once-every-two-weeks, and once-weekly administration. Interim analyses from the open-label, phase 3 FRONTIER4 long-term safety and efficacy study included 426 people with hemophilia A aged 1 year and older on denecimig prophylaxis (365 adults and adolescents with a median observation period of 0.50 years; 61 children with a median observation period of 0.33 years). For the primary study endpoint of safety, denecimig was found to be consistent with findings previously shared from the FRONTIER research program. Injection-site reactions (ISR) were reported at low rates in children (2.0% of injections) and in adolescents and adults (1.8% of injections), and all were mild and transient. No clinical evidence of neutralizing antibodies was observed. For the secondary study endpoints of efficacy, estimated mean annualized bleeding rates (ABRs) were consistent with findings from the FRONTIER research program across all dosing regimens and regardless of inhibitor status (ABRs: 0.75; 95% CI 0.60, 0.93 for adults and adolescents; 0.37; 95% CI 0.17, 0.76 for children). Across all doses, approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeds while receiving denecimig. The interim assessment of exploratory patient-reported outcomes (PROs) from the long-term FRONTIER4 study showed findings from prior FRONTIER trials were maintained long-term in all dosing frequencies studied, including improved joint pain for people aged 12 and older (Joint Pain Rating Scale, JPRS) and reduced treatment burden for those aged one and older (Hemophilia Treatment Experience Measure, Hemo-TEM). Across all age groups and dosing frequencies, 94.1% of 185 participants found the denecimig pen-injector easy or very easy to use, and 89.7% found it quick or very quick to prepare and inject (Hemophilia Device Assessment Tool, HDAT). New post hoc analyses of participants aged 12 and older with available thrombin generation data from the phase 3 FRONTIER2 and FRONTIER5 studies found that denecimig prophylaxis increased thrombin generation, a measure of the body's ability to form clots, into the normal reference range in adolescents and adults without excessive response. In September 2025, Novo Nordisk submitted denecimig for review to the US Food and Drug Administration (FDA) through a Biologics License Application (BLA). In addition to the latest denecimig data, Novo Nordisk is also presenting first-time results from the phase 3 open-label concizumab explorer10 trial evaluating the efficacy and safety of concizumab prophylaxis in 24 children below the age of 12 living with hemophilia A or B with inhibitors. In the trial, the estimated mean ABR on concizumab prophylaxis was 2.08 (95% CI 1.27, 3.41) compared to 11.51 (95% CI 7.75, 17.09) for previous on-demand treatment and the ABR ratio was 0.18 (95% CI 0.11, 0.29), representing an 82% reduction in ABR with concizumab compared to prior on-demand treatment. Eighty-three percent of the participants reported at least one on-treatment adverse event. Most events were mild in severity (152 out of 192 events) and with reported outcome as recovered (178 out of 192 events). Injection site reactions were infrequent, with 0.1 events per patient years of exposure. Twenty-nine percent of the participants reported serious adverse events. Denecimig is an investigational, bispecific antibody Factor VIIIa (FVIIIa) mimetic, designed as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults, adolescents, and children with hemophilia A (congenital FVIIIa deficiency), with or without inhibitors. Intended to be administered under the skin, denecimig bridges Factor IXa and Factor X. This action mimics FVIIIa function, which helps restore the body's thrombin generation capacity, helping blood to clot. Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody designed to block a protein in the body that stops blood from clotting. By blocking TFPI, concizumab leads to downstream production of thrombin, which helps to clot the blood and to prevent or reduce the frequency of bleeding episodes. Concizumab is currently approved under the name Alhemo in India, Brazil, and Switzerland for the treatment of adolescents and adults (12 years or older) with hemophilia A or B with inhibitors. In the US, Europe, Japan, and Australia, Alhemo is currently approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adolescents and adults (12 years or older) with hemophilia A or B, with or without inhibitors. It is not known if Alhemo is safe and effective in people receiving ongoing immune tolerance induction or in children younger than 12 years of age. The use of concizumab in children below 12 years of age with hemophilia A or B, with or without inhibitors, is investigational, safety and efficacy are not established and concizumab is not approved by regulatory authorities or available anywhere in the world. The FRONTIER clinical program investigates denecimig as a prophylaxis treatment for adults, adolescents, and children with hemophilia A, with or without inhibitors. The program includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4, and FRONTIER5. FRONTIER4 is the largest ongoing phase 3 trial of the FRONTIER program evaluating denecimig across all dosing frequencies in people of all ages, regardless of inhibitor status. The open-label trial aims to evaluate the long-term safety and efficacy of denecimig prophylaxis treatment in participants from across all FRONTIER trials who chose to continue on denecimig for the extension study. The FRONTIER4 long-term extension study includes 426 patients who decided to continue denecimig treatment after participating in the FRONTIER1, FRONTIER2, FRONTIER3, and FRONTIER5 studies. The current interim analysis covers a median observation period of 0.50 years in adults and adolescents and 0.33 years in children across the extension study, after patients have been in the pivotal phase 3 trials for a minimum of 26 to 52 weeks, depending on the FRONTIER trial they transitioned from. The 52-week phase 3 FRONTIER2 study compared the efficacy and safety profile of once-monthly and once-weekly denecimig versus on-demand clotting factor treatment and versus prior coagulation factor prophylaxis treatment in people aged 12 and older living with hemophilia A, with or without inhibitors.

Danish (OMX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig (Mim8) In Phase 3 Hemophilia a Frontier Extension Study

ALK B: Allergy Immunotherapy Leadership Will Drive Future Earnings Reassessment

ZEAL: Obesity Program Execution Will Support Future Upside Beyond Reset Expectations

EMBLA: Buybacks And Tighter Assumptions Will Shape Measured Future Upside Potential

DEMANT: Hearing Market Turnaround And Sector Inflection Shape Balanced Outlook

ChemoMetec A/S to Report Fiscal Year 2027 Results on Sep 09, 2027

AMBU B: Rising Competition Will Weigh On Future Share Performance

COLO B: Reset Expectations And New Products Will Shape Future Sentiment

Bavarian Nordic Gains Canadian Approval for Chikungunya Vaccine VIMKUNYA

H. Lundbeck A/S Announces Executive Changes

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Bioporto A/S Un-changes Earnings Guidance for the Full Year 2026